Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression

Biological Psychiatry

Volumn 53, Issue 8, 2003, Pages 707-742

  Manji, Husseini K ^a   Quiroz, Jorge A ^a   Sporn, Jonathan ^a   Payne, Jennifer L ^a   Denicoff, Kirk ^a   Gray, Neil A ^a   Zarate Jr , Carlos A ^a   Charney, Dennis S ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Bcl 2; Brain derived neurotrophic factor; Glutamate; Lithium; Mitogen activated protein kinase; Neuroplasticity

Indexed keywords

2 AMINO 4 PHOSPHONOMETHYL 3 HEPTENOIC ACID; 2 AMINO 7 PHOSPHONOHEPTANOIC ACID; AMANTADINE; AMPA RECEPTOR AGONIST; ANTIPARKINSON AGENT; CITALOPRAM; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOSERINE; DESIPRAMINE; DIZOCILPINE; FELBAMATE; GLUCOCORTICOID RECEPTOR ANTAGONIST; IMIPRAMINE; KETAMINE; LAMOTRIGINE; LIOTHYRONINE; LITHIUM; LY 392098; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENELZINE; PHOSPHODIESTERASE INHIBITOR; RILUZOLE; SEROTONIN UPTAKE INHIBITOR; SULFONAMIDE; THYROID HORMONE; THYROXINE; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZINC ION; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUCOCORTICOID; GLUTAMIC ACID DERIVATIVE; NERVE GROWTH FACTOR; PROTEIN BCL 2;

AGITATION; ANOREXIA; ASTHENIA; BRAIN FUNCTION; BRAIN NERVE CELL; CADAVER; CELL ACTIVITY; CELL SURVIVAL; CLINICAL TRIAL; CONCEPT FORMATION; DEPRESSION; DIFFICULT TO TREAT DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FATIGUE; GRANULOCYTOPENIA; HIPPOCAMPUS; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; MOLECULE; MONOAMINE NERVE CELL; MOOD DISORDER; MORPHOMETRICS; NAUSEA; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROANATOMY; NEUROCHEMISTRY; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; PARESTHESIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FAMILY; PSYCHIATRIC TREATMENT; RESTLESSNESS; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STRESS; SYNAPSE; VOMITING; WEIGHT REDUCTION; ANIMAL; CYTOLOGY; GROWTH, DEVELOPMENT AND AGING; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MAJOR DEPRESSION; MENTAL STRESS; NERVE CELL; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL SURVIVAL; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DEPRESSIVE DISORDER, MAJOR; GLUCOCORTICOIDS; GLUTAMATES; HIPPOCAMPUS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MOOD DISORDERS; NERVE GROWTH FACTORS; NEURONAL PLASTICITY; NEURONS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL;

EID: 0038147541     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(03)00117-3     Document Type: Review

References (215)

1. Aberg-Wistedt A, Hasselmark L, Stain-Malmgren R, Aperia B, Kjellman BF, Mathe AA (1998): Serotonergic 'vulnerability' in affective disorder: A study of the tryptophan depletion test and relationships between peripheral and central serotonin indexes in citalopram-responders. Acta Psychiatr Scand 97:374-380.
2. Adams JM, Cory S (1998): The Bcl-2 protein family: Arbiters of cell survival. Science 281:1322-1326.
3. Altamura C, Maes M, Dai J, Meltzer HY (1995): Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol 5(suppl):71-75.
4. Altamura CA, Mauri MC, Ferrara A, Moro AR, D'Andrea G, Zamberlan F (1993): Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 150:1731-1733.
5. Altshuler LL, Casanova MF, Goldberg TE, Kleinman JE (1990): The hippocampus and parahippocampus in schizophrenia, suicide, and control brains. Arch Gen Psychiatry 47:1029-1034.
6. Asanuma M, Nishibayashi S, Iwata E, Kondo Y, Nakanishi T, Vargas MG, et al (1996): Alterations of cAMP response element-binding activity in the aged rat brain in response to administration of rolipram, a cAMP-specific phosphodiesterase inhibitor. Brain Res Mol Brain Res 41:210-215.
7. Auer DP, Putz B, Kraft E, Lipinski B, Schill J, Holsboer F (2000): Reduced glutamate in the anterior cingulate cortex in depression: An in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 47:305-313.
8. Bahr BA, Bendiske J, Brown QB, Munirathinam S, Caba E, Rudin M, et al (2002): Survival signaling and selective neuroprotection through glutamatergic transmission. Exp Neurol 174:37-47.
9. Baumann B, Danos P, Krell D, Diekmann S, Leschinger A, Stauch R, et al (1999): Reduced volume of limbic system-affiliated basal ganglia in mood disorders: preliminary data from a postmortem study. J Neuropsychiatry Clin Neurosci 11:71-78.
10. Belanoff J, Flores B, Kalezhan M, Sund B, Schatzberg A (2001): Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 21:516-521.
11. Belanoff JK, Rothschild A, Cassidy F, DeBattista C, Baulieu EE, Schold C, et al (2002): An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 52:386-392.
12. Benes FM, Kwok EW, Vincent SL, Todtenkopf MS. (1998): A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol Psychiatry 44:88-97.
13. Benes FM, Vincent SL, Todtenkopf M (2001): The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects. Biol Psychiatry 50:395-406.
14. Berk M, Plein H, Ferreira D (2001): Platelet glutamate receptor supersensitivity in major depressive disorder. Clin Neuropharmacol 24:129-132.
15. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al (2000): Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354.
16. Bertolino A, Crippa D, di Dio S, Fichte K, Musmeci G, Porro V, et al (1988): Rolipram versus imipramine in inpatients with major, "minor" or atypical depressive disorder: A double-blind double-dummy study aimed at testing a novel therapeutic approach. Int Clin Psychopharmacol 3:245-253.
17. Beyer JL, Krishnan KR (2002): Volumetric brain imaging findings in mood disorders. Bipolar Disord 4:89-104.
18. Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Sastre-y-Hernandez M, et al (1988): Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur Arch Psychiatry Neurol Sci 238:2-6.
19. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME (1999): Cell survival promoted by the Ras-MAPK signaling pathway by transcription- dependent and -independent mechanisms. Science 286:1358-1362.
20. Bouras C, Kovari E, Hof PR, Riederer BM, Giannakopoulos P (2001): Anterior cingulate cortex pathology in schizophrenia and bipolar disorder. Acta Neuropathol (Berl) 102:373-379.
21. Bouron A, Chatton JY (1999): Acute application of the tricyclic antidepressant desipramine presynaptically stimulates the exocytosis of glutamate in the hippocampus. Neuroscience 90:729-736.
22. Bowley MP, Drevets WC, Ongur D, Price JL (2002): Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 52:404-412.
23. Boyer PA, Skolnick P, Fossom LH (1998): Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. J Mol Neurosci 10:219-233.
24. Brunson KL, Eghbal-Ahmadi M, Bender R, Chen Y, Baram TZ (2001): Long-term, progressive hippocampal cell loss and dysfunction induced by early-life administration of corticotropin-releasing hormone reproduce the effects of early-life stress. Proc Natl Acad Sci U S A 98:8856-8861.
25. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD (1999): A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 60:79-88.
26. Cameron HA, McKay RD (1999): Restoring production of hippocampal neurons in old age. Nat Neurosci 2:894-897.
27. Carmelli D, Reed T, DeCarli C (2002): A bivariate genetic analysis of cerebral white matter hyperintensities and cognitive performance in elderly male twins. Neurobiol Aging 23:413-420.
28. Castillo M, Kwock E, Courvoisie H, Hooper SR (2000): Proton MR spectroscopy in children with bipolar affective disorder: Preliminary observations. AJNR Am J Neuroradiol 21:832-838.
29. Chemerinski E, Robinson RG (2000): The neuropsychiatry of stroke. Psychosomatics 41:5-14.
30. Chen AC, Shin KH, Duman RS, Sanacora G (2001a): ECS-Induced mossy fiber sprouting and BDNF expression are attenuated by ketamine pretreatment. J ECT Mar 17:27-32.
31. Chen AC, Shirayama Y, Shin KH, Neve RL, Duman RS (2001b): Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect. Biol Psychiatry 49:753-762.
32. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT (2001): Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 50:260-265.
33. Chen DF, Schneider GE, Martinou JC, Tonegawa S (1997): Bcl-2 promotes regeneration of severed axons in mammalian CNS. Nature 385:434-439.
34. Chen DF, Tonegawa S (1998): Why do mature CNS neurons of mammals fail to re-establish connections following injury-functions of bcl-2. Cell Death Differ 5:816-822.
35. Chen G, Huang LD, Zeng WZ, Manji HK (2001): Mood stabilizers regulate cytoprotective and mRNA-binding proteins in the brain: Long-term effects on cell survival and transcript stability. Int J Neuropsychopharmacol 4:47-64.
36. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK (2000): Enhancement of hippocampal neurogenesis by lithium. J Neurochem 75:1729-1734.
37. Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH, et al (1999): The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 72:879-882.
38. Chierzi S, Strettoi E, Cenni MC, Maffei L (1999): Optic nerve crush: Axonal responses in wild-type and bcl-2 transgenic mice. J Neurosci 19:8367-8376.
39. Cotter D, Mackay D, Chana G, Beasley C, Landau S, Everall IP (2002): Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 12:386-394.
40. Cotter D, Mackay D, Landau S, Kerwin R, Everall I (2001): Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 58:545-553.
41. Coyle JT, Schwarcz R (2000): Mind glue: Implications of glial cell biology for psychiatry. Arch Gen Psychiatry 57:90-93.
42. Crane G (1959): Cycloserine as an antidepressant agent. Am J Psychiatry 115:1025-1026.
43. Czeh B, Michaelis T, Watanabe T, Frahm J, de Biurrun G, van Kampen M, et al (2001): Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci U S A 98:12796-12801.
44. Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, Moreno FA, et al (1999): Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: Implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 46:212-220.
45. Delgado PL, Price LH, Miller HL, Salomon RM, Licinio J, Krystal JH, et al (1991): Rapid serotonin depletion as a provocative challenge test for patients with major depression: Relevance to antidepressant action and the neurobiology of depression. Psychopharmacol Bull 27:321-330.
46. de Montigny C, Cournoyer G, Morissette R, Langlois R, Caille G (1983): Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system. Arch Gen Psychiatry 40:1327-1334.
47. DeVries AC, Joh HD, Bernard O, Hattori K, Hurn PD, Traystman RJ, et al (2001): Social stress exacerbates stroke outcome by suppressing Bcl-2 expression. Proc Natl Acad Sci U S A 98:11824-11828.
48. Dixon JF, Hokin LE (1998): Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc Natl Acad Sci U S A 95:8363-8368.
49. Doraiswamy PM, MacFall J, Krishnan KR, O'Connor C, Wan X, Benaur M, et al (1999): Magnetic resonance assessment of cerebral perfusion in depressed cardiac patients: Preliminary findings. Am J Psychiatry 156:1641-1643.
50. Drevets 2000Drevets WC (2000): Neuroimaging studies of mood disorders. Biol Psychiatry 48:813-829.
51. Drevets WC (2001): Neuroimaging and neuropathological studies of depression: Implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 11:240-249.
52. D'Sa C, Duman R (2002): Antidepressants and neuroplasticity. Bipolar Disord 4:183.
53. Du J, Gould TD, Manji HK (in press): Neurotrophic Signaling in Mood Disorders. In Finkel T and Gutkind G, editors. Signal Transduction and Human Health. New York, NY: John Wiley and Sons.
54. Duman RS, Malberg J, Thome J (1999): Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 46:1181-191.
55. Dyke HJ, Montana JG (2002): Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 11:1-13.
56. Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA, et al (1998): Neurogenesis in the adult human hippocampus. Nat Med 4:1313-1317.
57. Finkbeiner S (2000): CREB couples neurotrophin signals to survival messages. Neuron 25:11-14.
58. Fleischhacker WW, Hinterhuber H, Bauer H, Pflug B, Berner P, Simhandl C, et al (1992): A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology 26:59-64.
59. Francis D, Diorio J, Liu D, Meaney MJ (1999): Nongenomic transmission across generations of maternal behavior and stress responses in the rat. Science 286:1155-1158.
60. Fryer RH, Kaplan DR, Feinstein SC, Radeke MJ, Grayson DR, Kromer LF (1996): Developmental and mature expression of full-length and truncated TrkB receptors in the rat forebrain. J Comp Neurol 374:21-40.
61. Fujimaki K, Morinobu S, Duman RS (2000): Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus. Neuropsychopharmacology 22:42-51.
62. Gass P, Kretz O, Wolfer DP, Berger S, Tronche F, Reichardt HM, et al (2000): Genetic disruption of mineralocorticoid receptor leads to impaired neurogenesis and granule cell degeneration in the hippocampus of adult mice. EMBO Rep 1:447-451.
63. Gesing A, Bilang-Bleuel A, Droste SK, Linthorst AC, Holsboer F, Reul JM (2001): Psychological stress increases hippocampal mineralocorticoid receptor levels: Involvement of corticotropin-releasing hormone. J Neurosci 21:4822-4829.
64. Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, et al (2001): A placebo-controlled pilot study of the ampakine CX516 added to closapine in schizophrenia. J Clin Psychopharmacol 21:484-487.
65. Goggi J, Pullar IA, Carney SL, Bradford HF (2002): Modulation of neurotransmitter release induced by brain-derived neurotrophic factor in rat brain striatal slices in vitro. Brain Res 941:34-42.
66. Gold PW, Drevets WC, Charney DS (2002): New insights into the role of cortisol and the glucocorticoid receptor in severe depression. Biol Psychiatry 52:381-385.
67. Gold PW, Chrousos GP (2002): Organization of the stress system and its dysregulation in melancholic and atypical depression: High vs low CRH/NE states. Mol Psychiatry 7:254-275.
68. Gonzalez M, Ruggiero FP, Chang Q, Shi YJ, Rich MM, Kraner S, et al (1999): Disruption of Trkb-mediated signaling induces disassembly of postsynaptic receptor clusters at neuromuscular junctions. Neuron 24:567-583.
69. Gould E, Allan MD, McEwen BS (1990): Dendritic spine density of adult hippocampal pyramidal cells is sensitive to thyroid hormone. Brain Res 525:327-329.
70. Gould E, Tanapat P, Rydel T, Hastings N (2000): Regulation of hippocampal neurogenesis in adulthood. Biol Psychiatry 48:715-720.
71. Gould E, Woolley CS, McEwen BS (1991): The hippocampal formation: Morphological changes induced by thyroid, gonadal and adrenal hormones. Psychoneuroendocrinology 16:67-84.
72. Gould T, Manji H (2002): Signaling networks in the pathophysiology & treatment of mood disorders. J Psychosom Res 53:687-697.
73. Graham YP, Heim C, Goodman SH, Miller AH, Nemeroff CB (1999): The effects of neonatal stress on brain development: Implications for psychopathology. Dev Psychopathol 11:545-565.
74. Griebel G, Misslin R, Vogel E, Bourguignon JJ (1991): Behavioral effects of rolipram and structurally related compounds in mice: Behavioral sedation of cAMP phosphodiesterase inhibitors. Pharmacol Biochem Behav 39:321-323.
75. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, et al (2000): Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci U S A 97:6079-6084.
76. Haggerty JJ Jr, Prange AJ Jr (1995): Borderline hypothyroidism and depression. Annu Rev Med 46:37-46.
77. Hampson RE, Rogers G, Lynch G, Deadwyler SA (1998): Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance. J Neurosci 18:2740-2747.
78. Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM (2002): Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: Involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 80:589-597.
79. Hayashi T, Umemori H, Mishina M, Yamamoto T (1999): The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn. Nature 397:72-76.
80. Haydon PG (2001): GLIA: Listening and talking to the synapse. Nat Rev Neurosci 2:185-193.
81. Hebenstreit GF, Fellerer K, Fichte K, Fischer G, Geyer N, Meya U, et al (1989): Rolipram in major depressive disorder: Results of a double-blind comparative study with imipramine. Pharmacopsychiatry 22:156-160.
82. Heninger GR, Charney DS, Sternberg DE (1983): Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refractory depression. Arch Gen Psychiatry 40:1335-1342.
83. Heresco-Levy U, Javitt DC (1998): The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes. Eur Neuropsychopharmacol 8:141-152.
84. Hokin LE, Dixon JF, Los GV (2000): Acute inhibition but chronic upregulation and stabilization of glutamate uptake in synaptosomes by lithium. In Manji HK, Bowden CL and Belmaker RH, editors, Bipolar Medications: mechanisms of action. Washington DC: American Psychiatric Press, 65-85.
85. Holemans S, De Paermentier F, Horton RW, Crompton MR, Katona CL, Maloteaux JM (1993): NMDA glutamatergic receptors, labelled with [3H] MK-801, in brain samples from drug-free depressed suicides. Brain Res 616:138-143.
86. Holm KH, Cicchetti F, Bjorklund L, Boonman Z, Tandon P, Costantini LC, et al (2001): Enhanced axonal growth from fetal human bcl-2 transgenic mouse dopamine neurons transplanted to the adult rat striatum. Neuroscience 104:397-405.
87. Holsboer F (2000): The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23:477-501.
88. Horowski R, Sastre-Y-Hernandez M (1985): Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: Global evaluation of the preliminary reports. Curr Ther Res 38:23-29.
89. Huang X, Wu DY, Chen G, Manji H, Chen DF (2003): Support of retinal ganglion cell survival and axon regeneration by lithium through a Bcl-2-dependent mechanism. Invest Ophthalmol Vis Sci 44:347-354.
90. Huang Z, Ducharme Y, Macdonald D, Robichaud A (2001): The next generation of PDE4 inhibitors. Curr Opin Chem Biol 5:432-438.
91. Ingvar M, Ambros-Ingerson J, Davis M, Granger R, Kessler M, Rogers GA, et al (1997): Enhancement by an ampakine of memory encoding in humans. Exp Neurol 146:553-554.
92. Jacobs BL, Praag H, Gage FH (2000): Adult brain neurogenesis and psychiatry: A novel theory of depression. Mol Psychiatry 5:262-269.
93. Joffe RT (1997): Refractory depression: Treatment strategies, with particular reference to the thyroid axis. J Psychiatry Neurosci 22:327-331.
94. Jope RS (1999): Anti-bipolar therapy: Mechanism of action of lithium. Mol Psychiatry 4:117-128.
95. Kalaria RN, Prince AK (1986): Decreased neurotransmitter receptor binding in striatum and cortex from adult hypothyroid rats. Brain Res 364:268-274.
96. Karkanias NB, Papke RL (1999): Subtype-specific effects of lithium on glutamate receptor function. J Neurophysiol 81:1506-1512.
97. Kempermann G (2002): Regulation of adult hippocampal neurogenesis- implications for novel theories of major depression. Bipolar Disord 4:17-33.
98. Kempermann G, Kuhn HG, Gage FH (1997): More hippocampal neurons in adult mice living in an enriched environment. Nature 386:493-495.
99. Klein PS, Melton DA (1996): A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93:8455-8459.
100. Korte SM, De Kloet ER, Buwalda B, Bouman SD, Bohus B (1996): Antisense to the glucocorticoid receptor in hippocampal dentate gyrus reduces immobility in forced swim test. Eur J Pharmacol 301:19-25.
101. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, et al (2002): Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 7(suppl 1):S71-S80.
102. Lauterborn JC, Lynch G, Vanderklish P, Arai A, Gall CM (2000): Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci 20:8-21.
103. Legutko B, Li X, Skolnick P (2001): Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator. Neuropharmacology 40:1019-1027.
104. Lenox RH, Gould TD, Manji HK (2002): Endophenotypes in bipolar disorder. Am J Med Genet 114:391-406.
105. Levine J, Panchalingam K, Rapoport A, Gershon S, McClure RJ, Pettegrew JW (2000): Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry 47:586-593.
106. Li X, Bijur GN, Jope RS (2002): Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord 4:137-144.
107. Li X, Tizzano JP, Griffey K, Clay M, Lindstrom T, Skolnick P (2001): Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 40:1028-1033.
108. Lopez JF, Chalmers DT, Little KY, Watson SJ (1998): A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: Implications for the neurobiology of depression. Biol Psychiatry 43:547-573.
109. Lu EJ, Brown WJ (1977a): The developing caudate nucleus in the euthyroid and hypothyroid rat. J Comp Neurol 171:261-284.
110. Lu EJ, Brown WJ (1977b): An electron microscopic study of the developing caudate nucleus in euthyroid and hypothyroid states. Anat Embryol (Berl) 150:335-364.
111. Lynch G, Granger R, Ambros-Ingerson J, Davis CM, Kessler M, Schehr R (1997): Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp Neurol 145:89-92.
112. Lyons DM (2002): Stress, depression, and inherited variation in primate hippocampal and prefrontal brain development. Psychopharmacol Bull 36:27-43.
113. Lyons DM, Yang C, Sawyer-Glover AM, Moseley ME, Schatzberg AF (2001): Early life stress and inherited variation in monkey hippocampal volumes. Arch Gen Psychiatry 58:1145-1151.
114. Maes M, Verkerk R, Vandoolaeghe E, Lin A, Scharpe S (1998): Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: Modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand 97:302-308.
115. Mamounas LA, Blue ME, Siuciak JA, Altar CA (1995): Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J Neurosci 15:7929-7939.
116. Manev H, Uz T, Smalheiser NR, Manev R (2001): Antidepressants alter cell proliferation in the adult brain in vivo and in neural cultures in vitro. Eur J Pharmacol 411:67-70.
117. Manji H, Du J, Gould T (in press): The role of neurotrophic signaling pathways in mood disorders. In: Gutkind J, editor. Signal Transduction and Human Disease.
118. Manji H, Duman R (2001): Impairments of neuroplasticity and cellular resilience in severe mood disorder: Implications for the development of novel therapeutics. Psychopharmacol Bull 35:5-49.
119. Manji HK, Drevets WC, Charney DS (2001a): The cellular neurobiology of depression. Nat Med 7:541-547.
120. Manji HK, Lenox RH (2000): Signaling: Cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry 48:518-530.
121. Manji HK, Moore GJ, Chen G (2001b): Bipolar disorder: Leads from the molecular and cellular mechanisms of action of mood stabilizers. Br J Psychiatry 178(suppl 41):S107-S119.
122. Manji HK, Moore GJ, Rajkowska G, Chen G (2000): Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 5:578-593.
123. Mathis P, Schmitt E, Benatia M, Granier F, Ghisolfi J, Moron P (1988): Perturbations des acides amines plasmatiques et depression (Plasma amino acid disturbances and depression). Encephale 14:77-82.
124. Matsumoto T, Numakawa T, Adachi N, Yokomaku D, Yamagishi S, Takei N, et al (2001): Brain-derived neurotrophic factor enhances depolarization-evoked glutamate release in cultured cortical neurons. J Neurochem 79:522-530.
125. Mauri MC, Ferrara A, Boscati E, Bravin S, Zamberlan F, Alecci M, et al (1998): Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 37:124-129.
126. McEwen BS (1999): Stress and hippocampal plasticity. Annu Rev Neurosci 22:105-122.
127. McQuade R, Young AH (2000): Future therapeutic targets in mood disorders: The glucocorticoid receptor. Br J Psychiatry 177:390-395.
128. Meador-Woodruff JH, Hogg AJ Jr, Smith RE (2001): Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res Bull 55:631-640.
129. Mesulam MM (1999): Neuroplasticity failure in Alzheimer's disease: Bridging the gap between plaques and tangles. Neuron 24:521-529.
130. Michael-Titus AT, Bains S, Jeetle J, Whelpton R (2000): Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex - a possible mechanism of neuroprotection in major depression? Neuroscience 100:681-4.
131. Miguel-Hidalgo JJ, Rajkowska G (2002): Morphological brain changes in depression: can antidepressants reverse them? CNS Drugs 16:361-372.
132. Moore GJ, Bebchuk JM, Hasanat K, Chen G, Seraji-Bozorgzad N, Wilds IB, et al (2000a): Lithium increases N-acetyl-aspartate in the human brain: In vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry 48:1-8.
133. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK (2000b): Lithium-induced increase in human brain grey matter. Lancet 356:1241-1242.
134. Moore GJ, Galloway MP (2002): Magnetic resonance spectroscopy: neurochemistry and treatment effects in affective disorders. Psychopharmacol Bull 36:5-23.
135. Murray CJ, Lopez AD (1997): Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349:1436-1442.
136. Musselman DL, Evans DL, Nemeroff CB (1998): The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment. Arch Gen Psychiatry 55:580-592.
137. Nakamura S (1990): Antidepressants induce regeneration of catecholaminergic axon terminals in the rat cerebral cortex. Neurosci Lett 111:64-68.
138. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002): Neurobiology of depression. Neuron 34:13-25.
139. Nibuya M, Morinobu S, Duman RS (1995): Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15:7539-7547.
140. Nibuya M, Nestler EJ, Duman RS (1996): Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 16:2365-2372.
141. Nibuya M, Takahashi M, Russell DS, Duman RS (1999): Repeated stress increases catalytic TrkB mRNA in rat hippocampus. Neurosci Lett 267:81-84.
142. Nonaka S, Chuang DM (1998): Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 9:2081-2084.
143. Nonaka S, Hough CJ, Chuang DM (1998): Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci U S A 95:2642-2647.
144. Nowak G, Li Y, Paul IA (1996): Adaptation of cortical but not hippocampal NMDA receptors after chronic citalopram treatment. Eur J Pharmacol 295:75-85.
145. Nowak G, Ordway GA, Paul IA (1995a): Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 675:157-164.
146. Nowak G, Paul IA, Popik P, Young A, Skolnick P (1993): Ca2+ antagonists effect an antidepressant-like adaptation of the NMDA receptor complex. Eur J Pharmacol 247:101-102.
147. Nowak G, Redmond A, McNamara M, Paul IA (1995b): Swim stress increases the potency of glycine at the N-methyl-D-aspartate receptor complex. J Neurochem 64:925-927.
148. Ochs G, Penn RD, York M, Giess R, Beck M, Tonn J, et al (2000): A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:201-206.
149. O'Donnell JM (1993): Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J Pharmacol Exp Ther 264:1168-1178.
150. Oh YJ, Swarzenski BC, O'Malley KL (1996): Overexpression of Bcl-2 in a murine dopaminergic neuronal cell line leads to neurite outgrowth. Neurosci Lett 202:161-164.
151. Ongur D, Drevets WC, Price JL (1998): Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A 95:13290-13295.
152. Orford M, Mazurkiewicz D, Milligan G, Saggerson D (1991): Abundance of the alpha-subunits of Gi1, Gi2 and Go in synaptosomal membranes from several regions of the rat brain is increased in hypothyroidism. Biochem J 275(Pt 1):183-186.
153. Orford MR, Leung FC, Milligan G, Saggerson ED (1992): Treatment with triiodothyronine decreases the abundance of the alpha-subunits of Gi1 and Gi2 in the cerebral cortex. J Neurol Sci 112:34-37.
154. Owens MJ, Nemeroff CB (1999): Corticotropin-releasing factor antagonists in affective disorders. Expert Opin Investig Drugs 8:1849-1858.
155. Parkes JD, Calver DM, Zilkha KJ, Knill-Jones RP (1970): Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet 1:259-262.
156. Patapoutian A, Reichardt LF (2001): Trk receptors: Mediators of neurotrophin action. Curr Opin Neurobiol 11:272-280.
157. Patel PD, Lopez JF, Lyons DM, Burke S, Wallace M, Schatzberg AF (2000): Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain. J Psychiatr Res 34:383-392.
158. Paul IA, Trullas R, Skolnick P, Nowak G (1992): Down-regulation of cortical beta-adrenoceptors by chronic treatment with functional NMDA antagonists. Psychopharmacology (Berl) 106:285-287.
159. Payne J, Quiroz J, Gould T, Zarate C, Manji H (in press): The cellular neurobiology of bipolar disorder. In Charney DS, Nestler EJ (eds), Neurobiology of Mental Illness. New York: Oxford University Press.
160. Payne JL, Quiroz JA, Zarate CA, Manji HK (2002): Timing is everything: Does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation? Biol Psychiatry 52:921-926.
161. Pettmann B, Henderson CE (1998): Neuronal cell death. Neuron 20:633-647.
162. Phiel CJ, Klein PS (2001): Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41:789-813.
163. Pillay SS, Yurgelun-Todd DA, Bonello CM, Lafer B, Lava M, Renshaw PF (1997): A quantitative magnetic resonance imaging study of cerebral and cerebellar gray matter volume in primary unipolar major depression: Relationship to treatment response and clinical severity. Biol Psychiatry 42:79-84.
164. Poo MM (2001): Neurotrophins as synaptic modulators. Nat Rev Neurosci 2:24-32.
165. Prange AJ Jr (1996): Novel uses of thyroid hormones in patients with affective disorders. Thyroid 6:537-543.
166. Quiroz JA, Manji HK (2002): Enhancing synaptic plasticity and cellular resilience to develop novel, improved treatments for mood disorders. Dialogues Clin Neurosci 4:73-92.
167. Rajkowska G (2000a): Histopathology of the prefrontal cortex in major depression: What does it tell us about dysfunctional monoaminergic circuits? Prog Brain Res 126:397-412.
168. Rajkowska G (2000b): Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 48:766-777.
169. Rajkowska G (2002): Cell pathology in bipolar disorder. Bipolar Disord 4:105-116.
170. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, et al (1999): Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 45:1085-1098.
171. Reul JM, Holsboer F (2002): Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol 2:23-33.
172. Reus VI, Wolkowitz OM (2001): Antiglucocorticoid drugs in the treatment of depression. Expert Opin Investig Drugs 10:1789-1796.
173. Reynolds IJ, Miller RJ (1988): Tricyclic antidepressants block N-methyl-D-aspartate receptors: Similarities to the action of zinc. Br J Pharmacol 95:95-102.
174. Riccio A, Ahn S, Davenport CM, Blendy JA, Ginty DD (1999): Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons. Science 286:2358-2361.
175. Ruiz-Marcos A, Cartagena-Abella P, Martinez-Galan JR, Calvo R, Morreale de Escobar G, Escobar del Rey F (1994): Thyroxine treatment and the recovery of pyramidal cells of the cerebral cortex from changes induced by juvenile-onset hypothyroidism. J Neurobiol 25:808-818.
176. Ruiz-Marcos A, Sanchez-Toscano F, Escobar del Rey F, Morreale de Escobar G (1979): Severe hypothyroidism and the maturation of the rat cerebral cortex. Brain Res 162:315-329.
177. Ruiz-Marcos A, Sanchez-Toscano F, Escobar del Rey F, Morreale de Escobar G (1980): Reversible morphological alterations of cortical neurons in juvenile and adult hypothyroidism in the rat. Brain Res 185:91-102.
178. Sanchez MM, Young LJ, Plotsky PM, Insel TR (2000): Distribution of corticosteroid receptors in the rhesus brain: Relative absence of glucocorticoid receptors in the hippocampal formation. J Neurosci 20:4657-4668.
179. Sapolsky RM (1996): Stress, glucocorticoids, and damage to the nervous system: The current state of confusion. Stress 1:1-19.
180. Sapolsky RM (2000): Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 57:925-935.
181. Schinder AF, Berninger B, Poo M (2000): Postsynaptic target specificity of neurotrophin-induced presynaptic potentiation. Neuron 25:151-163.
182. Scott AI, Perini AF, Shering PA, Whalley LJ (1991): In-patient major depression: Is rolipram as effective as amitriptyline? Eur J Clin Pharmacol 40:127-129.
183. Simmons NE, Alden TD, Thorner MO, Laws ER Jr (2001): Serum cortisol response to transsphenoidal surgery for Cushing disease. J Neurosurg 95:1-8.
184. Skolnick P (1999): Antidepressants for the new millennium. Eur J Pharmacol 375:31-40.
185. Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R (1996): Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: Implications for the pharmacotherapy of depression. Pharmacopsychiatry 29:23-26.
186. Skolnick P, Legutko B, Li X, Bymaster FP (2001): Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacol Res 43:411-423.
187. Smith MA, Makino S, Kvetnansky R, Post RM (1995): Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 15:1768-1777.
188. Sporn J, Ghaemi SN, Sambur MR, Rankin MA, Recht J, Sachs GS, et al (2000): Pramipexole augmentation in the treatment of unipolar and bipolar depression: A retrospective chart review. Ann Clin Psychiatry 12:137-140.
189. Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE (1999): Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease. Biol Psychiatry 46:1595-1602.
190. Steffens DC, Helms MJ, Krishnan KR, Burke GL (1999): Cerebrovascular disease and depression symptoms in the cardiovascular health study. Stroke 30:2159-2166.
191. Steffens DC, Krishnan KR (1998): Structural neuroimaging and mood disorders: Recent findings, implications for classification, and future directions. Biol Psychiatry 43:705-712.
192. Stoll AL, Renshaw PF, Yurgelun-Todd DA, Cohen BM (2000): Neuroimaging in bipolar disorder: What have we learned? Biol Psychiatry 48:505-517.
193. Takahashi M, Terwilliger R, Lane C, Mezes PS, Conti M, Duman RS (1999): Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J Neurosci 19:610-618.
194. Takata K, Kitamura Y, Kakimura J, Kohno Y, Taniguchi T (2000): Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole. Brain Res 872:236-241.
195. Taylor WD, Payne ME, Krishnan KR, Wagner HR, Provenzale JM, Steffens DC, MacFall JR (2001): Evidence of white matter tract disruption in MRI hyperintensities. Biol Psychiatry 50:179-183.
196. Thoenen H (1995): Neurotrophins and neuronal plasticity. Science 270:593-598.
197. Thomas AJ, Ferrier IN, Kalaria RN, Davis S, O'Brien JT (2002): Cell adhesion molecule expression in the dorsolateral prefrontal cortex and anterior cingulate cortex in major depression in the elderly. Br J Psychiatry 181:129-134.
198. Thomas AJ, Ferrier IN, Kalaria RN, Woodward SA, Ballard C, Oakley A, et al (2000): Elevation in late-life depression of intercellular adhesion molecule-1 expression in the dorsolateral prefrontal cortex. Am J Psychiatry 157:1682-1684.
199. Thome J, Sakai N, Shin K, Steffen C, Zhang YJ, Impey S, et al (2000): CAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci 20:4030-4036.
200. Trullas R, Skolnick P (1990): Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 185:1-10.
201. Tsai G, Coyle JT (1995): N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol 46:531-540.
202. Ullian EM, Sapperstein SK, Christopherson KS, Barres BA (2001): Control of synapse number by glia. Science 291:657-661.
203. Vale S, Espejel MA, Dominguez JC (1971): Amantadine in depression. Lancet 2:437.
204. van Praag H, Kempermann G, Gage FH (1999): Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nat Neurosci 2:266-270.
205. Vincent S, Todtenkopf M, Benes F (1997): A comparison of the density of pyramidal and nonpyramydal neurons in the anterior cingulate cortex in schizophrenics and manic depressives. Society for Neuroscience 23:2199.
206. Wachtel H, Schneider HH (1986): Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors. Neuropharmacology 25:1119-1126.
207. Watanabe Y, Gould E, Daniels DC, Cameron H, McEwen BS (1992): Tianeptine attenuates stress-induced morphological changes in the hippocampus. Eur J Pharmacol 222:157-162.
208. Wei H, Qin ZH, Senatorov VV, Wei W, Wang Y, Qian Y, et al (2001): Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 106:603-612.
209. Wellman CL (2001): Dendritic reorganization in pyramidal neurons in medial prefrontal cortex after chronic corticosterone administration. J Neurobiol 49:245-253.
210. Young LT (2001): Postreceptor pathways for signal transduction in depression and bipolar disorder. J Psychiatry Neurosci 26(suppl):S17-S22.
211. Young LT (2002): Neuroprotective effects of antidepressant and mood stabilizing drugs. J Psychiatry Neurosci 27:8-9.
212. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G (2001): The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 276:31674-1683.
213. Zarate C, Quiroz J, Payne J, Manji H (2003): Modulators of the glutamatergic system: Implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull 36:35-83.
214. Zeller E, Stief HJ, Pflug B, Sastre-Y-Hernandez M (1984): Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 17:188-190.
215. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, et al (2000): Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919in major depression: The first 20 patients treated. J Psychiatr Res 34:171-181.